Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
Department of Biochemistry, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran.
Anticancer Agents Med Chem. 2020;20(7):800-808. doi: 10.2174/1871520620666200204100602.
MicroRNAs (miRs) are a group of small non-coding and single-stranded RNAs of 18 to 25 nucleotides. The study of microRNAs is one of the new ways to detect cancer. In this study, the serum expression of miR-223 in patients with GC was measured and compared with the control group.
This case-control study was conducted on 39 patients with GC and 39 control subjects who visited the Reza Radiotherapy and Oncology Center, Mashhad, Iran, due to gastrointestinal complaints. The demographic information was collected, and the serum levels of miR-223 were measured using the real-time PCR technique in all study subjects. The association between the GC of miR-223 and tumor staging and cancer progression was assessed.
The miR-223 expression in GC patients was 3.10-fold higher than that of the control group (p<0.0001). The miR-223 expression was significantly higher in the GC stages and grades compared to the control group (p<0.0001 each). However, there was no significant effect for age, smoking, and gender on miR- 223 expression in GC and controls. At the optimal cutoff value of 0.7436, the maximal sensitivity of 89.74% and specificity of 84.62% were achieved for miR-223 (p<0.001). The sensitivity and specificity for miR-223 for differentiating low grades from high grade were 92.31% and 73.08% (p=0.0003), and for differentiating low stages from the high stage was 81.82% and 39.29% respectively (p=0.696).
This study revealed that miR-223 could be considered as a non-invasive diagnostic marker in the early diagnosis of GC.
MicroRNAs (miRs) 是一组 18 到 25 个核苷酸的小非编码和单链 RNA。microRNAs 的研究是检测癌症的新方法之一。在这项研究中，测量了 GC 患者血清中 miR-223 的表达，并与对照组进行了比较。
这项病例对照研究在伊朗马什哈德的 Reza 放射肿瘤学和肿瘤中心对 39 名 GC 患者和 39 名因胃肠道抱怨而就诊的对照组进行。收集了所有研究对象的人口统计学信息，并使用实时 PCR 技术测量了 miR-223 的血清水平。评估了 miR-223 与 GC 肿瘤分期和癌症进展的相关性。
GC 患者的 miR-223 表达水平比对照组高 3.10 倍（p<0.0001）。与对照组相比，GC 分期和分级的 miR-223 表达明显更高（p<0.0001 各）。然而，年龄、吸烟和性别对 GC 和对照组 miR-223 表达没有显著影响。在最佳截断值 0.7436 时，miR-223 获得了 89.74%的最大灵敏度和 84.62%的特异性（p<0.001）。miR-223 用于区分低级别和高级别肿瘤的灵敏度和特异性分别为 92.31%和 73.08%（p=0.0003），用于区分低分期和高分期的灵敏度和特异性分别为 81.82%和 39.29%（p=0.696）。
本研究表明，miR-223 可作为 GC 早期诊断的非侵入性诊断标志物。
